Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Predicting median survival from early follow-up data: opportunities, limitations, and extensions.

Journal of the National Cancer Institute·2026
Same author

Unbiased avidity-based isolation of antigen-specific T cells.

Journal for immunotherapy of cancer·2026
Same author

Case Report: The "atoll sign": a case series on an unusual radiological pattern of immune-mediated pneumonitis.

Frontiers in immunology·2026
Same author

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

Nature communications·2026

Related Experiment Video

Updated: Sep 14, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC.

Maliazurina B Saad1, Qasem Al-Tashi1, Lingzhi Hong1,2

  • 1Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Nature Communications
|July 24, 2025
PubMed
Summary

A new machine learning model, A-STEP, predicts individual benefit from adding chemotherapy to immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC). This approach improves treatment selection beyond PD-L1, enhancing progression-free survival.

More Related Videos

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.7K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K

Related Experiment Videos

Last Updated: Sep 14, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.7K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K

Area of Science:

  • Oncology
  • Computational Biology
  • Genomics

Background:

  • Immune checkpoint inhibitors (ICIs) improve survival in advanced non-small cell lung cancer (NSCLC).
  • Current guidance for selecting between ICI monotherapy and combination chemotherapy is limited.
  • Single biomarkers like PD-L1 are insufficient for predicting treatment response.

Purpose of the Study:

  • To develop a machine learning model predicting individual benefit from adding chemotherapy to ICIs in advanced NSCLC.
  • To estimate heterogeneous treatment effects using clinicogenomic data.
  • To provide prospective guidance for optimizing NSCLC immunotherapy selection.

Main Methods:

  • Developed an integrated machine learning model, A-STEP (Attention-based Scoring for Treatment Effect Prediction).
  • Utilized clinicogenomic data from four large cohorts (totaling 2,220 patients).
  • Calculated benefit scores using 28 genomic and 6 clinical features to predict treatment effect.

Main Results:

  • A-STEP achieved the largest reduction in 3-month progression risk, improving weighted risk reduction by 13-23% compared to stand-alone models.
  • The model recommended treatment changes for over 50% of patients, predominantly favoring ICI-Chemo.
  • Simulations on an external cohort showed improved 2-year progression-free survival with A-STEP guided treatment (HR=0.60 for ICI-Mono, HR=0.58 for ICI-Chemo).
  • Key predictive features included FBXW7, APC, and PD-L1.

Conclusions:

  • Machine learning can address critical gaps in NSCLC immunotherapy selection by modeling treatment heterogeneity.
  • A-STEP enables precision medicine by moving beyond conventional biomarker limitations.
  • This approach optimizes treatment decisions for advanced NSCLC patients, improving outcomes.